Suven to present results from Phase-2a study of Ropanicant at Neuroscience 2024 EP News Bureau Oct 3, 2024 Suven plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to…
